Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03390504
Title	A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations (THOR)
Acronym	THOR
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Janssen Research & Development, LLC
Indications	transitional cell carcinoma
Therapies	Pembrolizumab Erdafitinib Docetaxel + Vinflunine
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| POL \| NLD \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BGR \| BEL \| AUT \| AUS \| ARG